KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Preferred Stock Liabilities (2016)

CRISPR Therapeutics AG (CRSP) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $10.4 million as the latest value for Q3 2016.

  • Quarterly Preferred Stock Liabilities changed N/A to $10.4 million in Q3 2016 from the year-ago period, while the trailing twelve-month figure was $10.4 million through Sep 2016, changed N/A year-over-year, with the annual reading at $30.4 million for FY2015, N/A changed from the prior year.
  • Preferred Stock Liabilities hit $10.4 million in Q3 2016 for CRISPR Therapeutics AG, down from $30.4 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $30.4 million in Q4 2015 to a low of $10.4 million in Q3 2016.